A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bepler, G.
Oh, Y.
Burris, H.
Cleverly, A.
Lahn, M.
Herbst, R. S.
机构：
[1] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Sarah Cannon Res Inst, Ashville, TN USA
[4] Eli Lilly & Co, Erlwood, England
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7543
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
    Oh, Y.
    Herbst, R.
    Burris, H.
    Cleverly, A.
    Lahn, M.
    Bepler, G.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 35 - 35
  • [2] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    [J]. Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [3] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    [J]. ONCOLOGIST, 2008, 13 : 14 - 20
  • [4] Phase II study of tarceva as third-line treatment in advanced non-small cell lung cancer
    de Castro, Javier
    Pallares, Cinta
    Gurpide, Alfonso
    Cobo, Manuel
    Paz-Ares, Luis
    Gonzalez-Larriba, Jose Luis
    Insa, Amelia
    Domine, Manuel
    Sanchez, Rocio
    Massuti, Bartomeu
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 236 - 236
  • [5] Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
    David Rossi
    Donatella Dennetta
    Marcello Ugolini
    Vincenzo Catalano
    Paolo Alessandroni
    Paolo Giordani
    Anna Maria Baldelli
    Virginia Casadei
    Francesco Graziano
    S. Luzi Fedeli
    [J]. Targeted Oncology, 2010, 5 : 231 - 235
  • [6] Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
    Rossi, David
    Dennetta, Donatella
    Ugolini, Marcello
    Catalano, Vincenzo
    Alessandroni, Paolo
    Giordani, Paolo
    Baldelli, Anna Maria
    Casadei, Virginia
    Graziano, Francesco
    Fedeli, S. Luzi
    [J]. TARGETED ONCOLOGY, 2010, 5 (04) : 231 - 235
  • [7] A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC)
    Oton, Ana B.
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Kim, Sang-We
    Subramanian, Kirushnakumar
    Desai, Chirag
    Shuster, Dale
    Goldberg, Terri
    Zahir, Hamim
    Dutta, Dipen
    Chen, Shuquan
    Von Roemeling, Richard
    von Pawel, Joachim
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [8] Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
    Oh, Yun
    Herbst, Roy S.
    Burris, Howard
    Cleverly, Ann
    Musib, Luna
    Lahn, Michael
    Bepler, Gerold
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1135 - 1141
  • [9] Adverse effects and associated costs with second- and third-line therapies for non-small cell lung cancer
    Ye, X.
    Darkow, T.
    Reyes, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Behera, Madhusmita
    Subramanian, Janakiraman
    Saba, Nabil F.
    Kono, Scott A.
    Gal, Anthony A.
    Sica, Gabriel
    Harvey, R. Donald
    Chen, Zhengjia
    Klass, Carmen M.
    Shin, Dong M.
    Fu, Haian
    Sun, Shi-yong R.
    Govindan, Ramaswamy
    Khuri, Fadlo R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 369 - 372
12345